Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pINGmuTyr
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Electroporation
01
Overview
pINGmuTyr is a murine tyrosinase DNA vaccine developed for the treatment of malignant melanoma. Administered via electroporation, its mechanism of action involves inducing CD8+ T cell responses specifically targeting tyrosinase, a melanosomal antigen. This aims to stimulate the patient's immune system to recognize and attack melanoma cells expressing tyrosinase. It was evaluated in a Phase I clinical trial.
- Other names
- huTyr vaccinepINGmuTyrcanine melanoma DNA vaccine
02
Targets
TYR (Tyrosinase)
Beyond the preview
Go deeper on pINGmuTyr.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pINGmuTyr.